Search

Your search keyword '"Caporali, C."' showing total 17 results
Start Over Author "Caporali, C." Publisher elsevier bv
Sorry, I don't understand your search. ×
17 results on '"Caporali, C."'

1. OC.11.1: UNDERDILATION STRATEGY FOR TIPS PLACEMENT REDUCES INCIDENCE OF OVERT HEPATIC ENCEPHALOPATHY WITHOUT AFFECTING CLINICAL EFFICACY AND SURVIVAL: RESULTS OF A MULTICENTER PROSPECTIVE ITALIAN STUDY

Author

Saltini, D., primary, Nardelli, S., additional, Addotti, V., additional, Biribin, L., additional, Guasconi, T., additional, Gioia, S., additional, Caporali, C., additional, Bianchini, M., additional, Rosi, M., additional, Roccarina, D., additional, Ridola, L., additional, Casari, F., additional, Prampolini, F., additional, Indulti, F., additional, Cuffari, B., additional, Ragozzino, L., additional, De Maria, N., additional, Colecchia, A., additional, Senzolo, M., additional, Merli, M., additional, Marra, F., additional, Riggio, O., additional, Vizzutti, F., additional, and Schepis, F., additional

Published
2024
Full Text
View/download PDF

2. BOC.02.7: UNDERDILATED NEOADJUVANT-TIPS IN PATIENTS WITH CIRRHOSIS AND PORTAL HYPERTENSION CANDIDATES TO OPERATIVE INTERVENTIONS

Author

Saltini, D., primary, Guasconi, T., additional, Ingravallo, A., additional, Indulti, F., additional, Caporali, C., additional, Gitto, S., additional, Falcini, M., additional, Bianchini, M., additional, Cuffari, B., additional, Scoppettuolo, R., additional, Prampolini, F., additional, Casari, F., additional, De Maria, N., additional, Marra, F., additional, Colecchia, A., additional, Vizzutti, F., additional, and Schepis, F., additional

Published
2024
Full Text
View/download PDF

3. BOC.02.4: EPISODIC OVERT HEPATIC ENCEPHALOPATHY AFTER TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT DOES NOT INCREASE MORTALITY IN PATIENTS WITH CIRRHOSIS

Author

Nardelli, S., primary, Riggio, O., additional, Marra, F., additional, Gioia, S., additional, Saltini, D., additional, Bellafante, D., additional, Adotti, V., additional, Guasconi, T., additional, Ridola, L., additional, Rosi, M., additional, Caporali, C., additional, Fanelli, F., additional, Roccarina, D., additional, Bianchini, M., additional, Indulti, F., additional, Spagnoli, A., additional, Merli, M., additional, Vizzutti, F., additional, and Schepis, F., additional

Published
2024
Full Text
View/download PDF

4. Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis

Author

Nardelli, S., primary, Riggio, O., additional, Marra, F., additional, Gioia, S., additional, Saltini, D., additional, Bellafante, D., additional, Adotti, V., additional, Guasconi, T., additional, Ridola, L., additional, Rosi, M., additional, Caporali, C., additional, Fanelli, F., additional, Roccarina, D., additional, Bianchini, M., additional, Indulti, F., additional, Spagnoli, A., additional, Merli, M., additional, Vizzutti, F., additional, and Schepis, F., additional

Published
2024
Full Text
View/download PDF

5. Response to “Hepatic encephalopathy and survival after transjugular intra-hepatic portosystemic shunt: do spontaneous portosystemic shunts matter?”

Author

Nardelli, S., primary, Riggio, O., additional, Marra, F., additional, Gioia, S., additional, Saltini, D., additional, Bellafante, D., additional, Adotti, V., additional, Guasconi, T., additional, Ridola, L., additional, Rosi, M., additional, Caporali, C., additional, Fanelli, F., additional, Roccarina, D., additional, Bianchini, M., additional, Indulti, F., additional, Spagnoli, A., additional, Merli, M., additional, Schepis, F., additional, and Vizzutti, F., additional

Published
2024
Full Text
View/download PDF

6. Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis

Author

Nardelli, Silvia, primary, Riggio, Oliviero, additional, Marra, Fabio, additional, Gioia, Stefania, additional, Saltini, Dario, additional, Bellafante, Daniele, additional, Adotti, Valentina, additional, Guasconi, Tomas, additional, Ridola, Lorenzo, additional, Rosi, Martina, additional, Caporali, C., additional, Fanelli, Fabrizio, additional, Roccarina, Davide, additional, Bianchini, Marcello, additional, Indulti, Federica, additional, Spagnoli, Alessandra, additional, Merli, Manuela, additional, Vizzutti, Francesco, additional, and Schepis, Filippo, additional

Published
2023
Full Text
View/download PDF

8. TIPS under-dilation strategy with new controlled expansion endoprosthesis: A hemodynamic and imaging confirmation of its feasibility

Author

Saltini, D., primary, Caporali, C., additional, Indulti, F., additional, Casari, F., additional, Prampolini, F., additional, Felaco, D., additional, Battinelli, G., additional, Bianchini, M., additional, Guasconi, T., additional, Cuffari, B., additional, Zanetto, A., additional, Olivieri, T., additional, Assirati, G., additional, Serra, V., additional, Catellani, B., additional, Guidetti, C., additional, Guerrini, G.P., additional, Ballarin, R., additional, Magistri, P., additional, De Maria, N., additional, Di Sandro, S., additional, Torricelli, P., additional, Girardis, M., additional, Villa, E., additional, Colecchia, A., additional, Di Benedetto, F., additional, and Schepis, F., additional

Published
2023
Full Text
View/download PDF

9. Transjugular intra-hepatic portosystemic shunt (TIPS) in elderly patients: preliminary analysis of a multicenter retrospective cohort.

Author

Roccarina, D., primary, Turco, L., additional, Campani, C., additional, Saltini, D., additional, Aspite, S., additional, Calvaruso, V., additional, Arena, U., additional, Senzolo, M., additional, Fanelli, F., additional, Caporali, C., additional, Gitto, S., additional, Citone, M., additional, Di Bonaventura, C., additional, Schepis, F., additional, Vizzutti, F., additional, Riggio, O., additional, Burra, P., additional, Villa, E., additional, Cammà, C., additional, Marra, F., additional, and Bianchini, M., additional

Published
2022
Full Text
View/download PDF

10. Neoangiogenic transcriptomic signature identifies HCCs with worse response to treatment: long-term results of a prospective study

Author

Pivetti, A., primary, Borghi, A., additional, Critelli, R., additional, Lei, B., additional, Casari, F., additional, Del Buono, M., additional, Milosa, F., additional, Bianchini, M., additional, Caporali, C., additional, Bernabucci, V., additional, De Maria, N., additional, Di Benedetto, F., additional, Magistri, P., additional, and Villa, E., additional

Published
2020
Full Text
View/download PDF

11. Long-term prospective study of development of hepatocellular carcinoma in compensated cirrhosis

Author

Pivetti, A., primary, Todesca, P., additional, Bernabucci, V., additional, Lei, B., additional, Buono, M. Del, additional, Turco, L., additional, Schepis, F., additional, Bianchini, M., additional, De Maria, N., additional, Romagnoli, D., additional, Carulli, L., additional, Casari, F., additional, Caporali, C., additional, Felaco, D., additional, and Villa, E., additional

Published
2020
Full Text
View/download PDF

16. Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis

Author

Tommaso Di Maira, Stefano Fagiuoli, Rita Golfieri, Umberto Arena, Fabio Marra, Stefano Gitto, Stefano Colopi, Alessandro Cannavale, Filippo Schepis, Pietro Torricelli, Luca S. Belli, Pietro Quaretti, Giacomo Laffi, Angelo Luca, Cristian Caporali, Roberto Agazzi, Roberto Miraglia, Federico Banchelli, Nicola De Maria, Guido Marzocchi, Ilaria Fiorina, Roberto Nani, Antonio Rampoldi, Erica Villa, Mario De Santis, Raffaele Bruno, Lorenzo Paolo Moramarco, Guadalupe Garcia-Tsao, Aldo Airoldi, Francesco Vizzutti, Fabrizio Fanelli, L. Rega, Matteo Renzulli, Cristina Mosconi, Fabrizio Di Benedetto, Schepis, F, Vizzutti, F, Garcia-Tsao, G, Marzocchi, G, Rega, L, De Maria, N, Di Maira, T, Gitto, S, Caporali, C, Colopi, S, De Santis, M, Arena, U, Rampoldi, A, Airoldi, A, Cannavale, A, Fanelli, F, Mosconi, C, Renzulli, M, Agazzi, R, Nani, R, Quaretti, P, Fiorina, I, Moramarco, L, Miraglia, R, Luca, A, Bruno, R, Fagiuoli, S, Golfieri, R, Torricelli, P, Di Benedetto, F, Belli, L, Banchelli, F, Laffi, G, Marra, F, Villa, E, Schepis, Filippo, Vizzutti, Francesco, Garcia-Tsao, Guadalupe, Marzocchi, Guido, Rega, Luigi, De Maria, Nicola, Di Maira, Tommaso, Gitto, Stefano, Caporali, Cristian, Colopi, Stefano, De Santis, Mario, Arena, Umberto, Rampoldi, Antonio, Airoldi, Aldo, Cannavale, Alessandro, Fanelli, Fabrizio, Mosconi, Cristina, Renzulli, Matteo, Agazzi, Roberto, Nani, Roberto, Quaretti, Pietro, Fiorina, Ilaria, Moramarco, Lorenzo, Miraglia, Roberto, Luca, Angelo, Bruno, Raffaele, Fagiuoli, Stefano, Golfieri, Rita, Torricelli, Pietro, Di Benedetto, Fabrizio, Belli, Luca Saverio, Banchelli, Federico, Laffi, Giacomo, Marra, Fabio, and Villa, Erica

Subjects
Male, medicine.medical_specialty, Cirrhosis, medicine.medical_treatment, Liver, liver, portal hypertensive bleeding, portal hypertensive complications, treatment, vascular disease, Hemodynamics, Inferior vena cava, 03 medical and health sciences, 0302 clinical medicine, Model for End-Stage Liver Disease, Vascular Disease, Ascites, medicine, Humans, Prospective Studies, Aged, Hepatology, Vascular disease, business.industry, Incidence, Gastroenterology, Stent, Middle Aged, medicine.disease, Fibrosis, Surgery, Treatment, Treatment Outcome, Italy, Portal Hypertensive Bleeding, medicine.vein, Hepatic Encephalopathy, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Portasystemic Shunt, Transjugular Intrahepatic, medicine.symptom, business, Transjugular intrahepatic portosystemic shunt
Abstract

Background & Aims: Portosystemic encephalopathy (PSE) is a major complication of trans-jugular intrahepatic porto-systemic shunt (TIPS) placement. Most devices are self-expandable polytetrafluoroethylene-covered stent grafts (PTFE-SGs) that are dilated to their nominal diameter (8 or 10 mm). We investigated whether PTFE-SGs dilated to a smaller caliber (under-dilated TIPS) reduce PSE yet maintain clinical and hemodynamic efficacy. We also studied whether under-dilated TIPS self-expand to nominal diameter over time. Methods: We performed a prospective, non-randomized study of 42 unselected patients with cirrhosis who received under-dilated TIPS (7 and 6 mm) and 53 patients who received PTFE-SGs of 8 mm or more (controls) at referral centers in Italy. After completion of this study, dilation to 6 mm became the standard and 47 patients were included in a validation study. All patients were followed for 6 months; Doppler ultrasonography was performed 2 weeks and 3 months after TIPS placement and every 6 months thereafter. Stability of PTFE-SG diameter was evaluated by computed tomography analysis of 226 patients with cirrhosis whose stent grafts increased to 6, 7, 8, 9, or 10 mm. The primary outcomes were incidence of at least 1 episode of PSE grade 2 or higher during follow up, incidence of recurrent variceal hemorrhage or ascites, incidence of shunt dysfunction requiring TIPS recanalization, and reduction in porto-caval pressure gradient. Results: PSE developed in a significantly lower proportion of patients with under-dilated TIPS (27%) than controls (54%) during the first year after the procedure (P =.015), but the proportions of patients with recurrent variceal hemorrhage or ascites did not differ significantly between groups. No TIPS occlusions were observed. These results were confirmed in the validation cohort. In an analysis of self-expansion of stent grafts, during a mean follow-up period of 252 days after placement, none of the PTFE-SGs self-expanded to the nominal diameter in hemodynamically relevant sites (such as portal and hepatic vein vascular walls). Conclusions: In prospective, non-randomized study of patients with cirrhosis, we found under-dilation of PTFE-SGs during TIPS placement to be feasible, associated with lower rates of PSE, and effective.

Published
2018

17. Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis

Author

Cristian Caporali, Cristina Tata, Monica Luongo, Ramona Zecchini, Aimilia Karampatou, Elena Turola, Barbara Lei, Stefano Gitto, Mariagrazia Del Buono, Beatrice Zambotto, Salvatore Petta, Ranka Vukotic, Marco Marietta, Anna Ferrari, Rosina Maria Critelli, Giovanni Fornaciari, Filippo Schepis, Stefano Colopi, Veronica Bernabucci, Calogero Cammà, Dominique Valla, Luisa Simoni, Erica Villa, Nicola De Maria, Susanna Schianchi, Villa, E, Camma', C, Marietta, M, Luongo, M, Critelli, R, Colopi, S, Tata, C, Zecchini, R, Gitto, S, Petta, S, Lei, B, Bernabucci, V, Vukotic, R, De Maria, N, Schepis, F, Karampatou, A, Caporali, C, Simoni, L, Del Buono, M, Zambotto, B, Turola, E, Fornaciari, G, Schianchi, S, Ferrari, A, and Valla, D

Subjects
medicine.medical_specialty, Cirrhosis, Intention-to-treat analysis, Hepatology, business.industry, cirrhosis, Gastroenterology, Portal vein trombosis, Enoxaparin, enoxaparin, cirrhosis, portal thrombosis, medicine.disease, Surgery, Portal vein thrombosis, law.invention, Spontaneous bacterial peritonitis, Model for End-Stage Liver Disease, Randomized controlled trial, law, Hepatocellular carcinoma, Medicine, Portal hypertension, business
Abstract

BACKGROUND & AIMS: We performed a randomized controlled trial to evaluate the safety and efficacy of enoxaparin, a low-molecular-weight heparin, in preventing portal vein thrombosis (PVT) in patients with advanced cirrhosis. METHODS: In a nonblinded, single-center study, 70 outpatients with cirrhosis (Child-Pugh classes B7-C10) with demonstrated patent portal veins and without hepatocellular carcinoma were assigned randomly to groups that were given enoxaparin (4000 IU/day, subcutaneously for 48 weeks; n = 34) or no treatment (controls, n = 36). Ultrasonography (every 3 months) and computed tomography (every 6 months) were performed to check the portal vein axis. The primary outcome was prevention of PVT. Radiologists and hepatologists that assessed outcomes were blinded to group assignments. Analysis was by intention to treat. RESULTS: At 48 weeks, none of the patients in the enoxaparin group had developed PVT, compared with 6 of 36 (16.6%) controls (P = .025). At 96 weeks, no patient developed PVT in the enoxaparin group, compared with 10 of 36 (27.7%) controls (P = .001). At the end of the follow-up period, 8.8% of patients in the enoxaparin group and 27.7% of controls developed PVT (P = .048). The actuarial probability of PVT was lower in the enoxaparin group (P = .006). Liver decompensation was less frequent among patients given enoxaparin (11.7%) than controls (59.4%) (P < .0001); overall values were 38.2% vs 83.0%, respectively (P < .0001). The actuarial probability of liver decompensation was lower in the enoxaparin group (P < .0001). Eight patients in the enoxaparin group and 13 controls died. The actuarial probability of survival was higher in the enoxaparin group (P = .020). No relevant side effects or hemorrhagic events were reported. CONCLUSIONS: In a small randomized controlled trial, a 12-month course of enoxaparin was safe and effective in preventing PVT in patients with cirrhosis and a Child-Pugh score of 7-10. Enoxaparin appeared to delay the occurrence of hepatic decompensation and to improve survival.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results